Associations of CYP1 polymorphisms with risk of prostate cancer: an updated meta-analysis.

BACKGROUND: Previous studies on the association between CYP1 polymorphisms and the susceptibility of prostate cancer showed inconsistent results. This study was conducted to derive a better estimation of the association.

METHODS: A systematic search was carried out using the PubMed, EMBASE, Cochrane Library and CNKI databases for relevant articles published till August 15, 2018. Odds ratios, and 95% confidence intervals were obtained by fixed-effect or random-effect model.

RESULTS: A significant association of CYP1A1 rs1048943 polymorphism and PCa was found in the overall (B [the minor allele] vs. A [the major allele]: OR =1.20, 95% CI =1.04-1.39, P =0.014; AB vs. AA: OR =1.24, 95% CI =1.02-1.51, P =0.029; BB + AB vs. AA: OR =1.25, 95% CI =1.04-1.50, P =0.018) and Asian (B vs. A: OR =1.32, 95% CI =1.11-1.56, P =0.001; BB vs. AA: OR =1.81, 95% CI =1.20-2.72, P =0.005; AB vs. AA: OR =1.30, 95% CI =1.03-1.64, P =0.029; BB + AB vs. AA: OR =1.38, 95% CI =1.11-1.73, P =0.004; BB vs. AA + AB: OR =1.58, 95% CI =1.08-2.01, P =0.019) populations, but not in the Caucasian population. Moreover, we found that rs4646903 polymorphism increased the risk of PCa in the Asian (AB vs. AA: OR =1.43, 95% CI =1.13-1.80, P =0.003) and Caucasian (BB vs. AA: OR =2.12, 95% CI =1.29-3.49, P=0.003) populations.

CONCLUSION: This meta-analysis revealed a clear association between rs1048943 and rs4646903 polymorphisms of the CYP1A1 gene but not between CYP1B1 rs10012, rs162549, rs1800440, and rs2551188 polymorphisms and PCa risk.